Prevention of HIV/AIDS

The Family Health Centers at NYU Langone Receives $2 Million CDC Grant to Expand Effective HIV Prevention

Retrieved on:

Wednesday, August 4, 2021

New York University, Midtown Manhattan, NYU Langone Health, Langone, Prevention of HIV/AIDS, Manhattan, New York City

BROOKLYN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Affirming the success of its HIV prevention programs and support strategies, the Family Health Centers at NYU Langone has received an additional five-year, $2 million grant through the Centers for Disease Control and Prevention's (CDC) Comprehensive High-Impact HIV Prevention Programs for Community Based Organizations.

Key Points:

BROOKLYN, N.Y., Aug. 4, 2021 /PRNewswire/ -- Affirming the success of its HIV prevention programs and support strategies, the Family Health Centers at NYU Langone has received an additional five-year, $2 million grant through the Centers for Disease Control and Prevention's (CDC) Comprehensive High-Impact HIV Prevention Programs for Community Based Organizations.
"This competitive grant validates the progress and potential of our outreach efforts to prevent HIV and support our community," says Larry K. McReynolds , executive director of the Family Health Centers at NYU Langone and clinical associate professor in the Department of Population Health at NYU Grossman School of Medicine.
"For more than 30 years, the Family Health Centers at NYU Langone has been at the forefront of HIV care and prevention," says Finn Schubert, network HIV program director at the Family Health Centers at NYU Langone.
HIV prevention partnership with Turning Point Brooklyn , which provides education, housing, and related servicesin the Sunset Park, Brooklyn, community.

LifeStyles® Publicly Traded Campaign Lauded During Advertising Award Season for Creative Communication around STI Awareness

Retrieved on:

Thursday, July 29, 2021

Sexual health, LifeStyles Condoms, Medical specialties, Prevention of HIV/AIDS, HIV/AIDS, Condom, Lifestyle, Female condom, Subaru Tecnica International, Human reproduction, Health

ISELIN, N.J., July 29, 2021 /PRNewswire/ -- Leading sexual wellness company, LifeStyles Healthcare, is excited to announce a slew of recent accolades for its Publicly Traded campaign, which have contributed to making the campaign the most awarded sexual wellness campaign in 2021.

Key Points:

ISELIN, N.J., July 29, 2021 /PRNewswire/ -- Leading sexual wellness company, LifeStyles Healthcare, is excited to announce a slew of recent accolades for its Publicly Traded campaign, which have contributed to making the campaign the most awarded sexual wellness campaign in 2021.
Thanks to its breakthrough way of raising STI awareness, Publicly Traded took home 1 Grand Prix, 1 Gold, 4 Silvers and 5 Bronzes during the 2021 advertising and marketing award season from the world's most prestigious organizations, including Clio and Cannes Lions.
Prompted by reports indicating STI rates were at an all-time high, LifeStyles Healthcare piloted a new campaign in August 2020 that went beyond traditional education, offering an instant, accessible way for consumers to stay protected.
The campaign platform stimulates purchase behavior through a smart data visualization designed to make condoms more accessible through discounting and instant online purchasing.

Trojan® Brand Condoms commissions survey to understand the nation's attitude towards dating and sex ahead of COVID-19 restrictions being lifted

Retrieved on:

Wednesday, July 28, 2021

Prevention of HIV/AIDS, HIV/AIDS, Sexual health, Medical specialties, Human reproduction, Health, Carter-Wallace, Trojan, Condom, Female condom, Safe sex

To fully comprehend the nation's viewpoint on what the 'new normal' might be, Trojan Brand Condoms has commissioned a survey with OnePoll to depict how the events over the last 16 months have impacted people's love and sex lives.

Key Points:

To fully comprehend the nation's viewpoint on what the 'new normal' might be, Trojan Brand Condoms has commissioned a survey with OnePoll to depict how the events over the last 16 months have impacted people's love and sex lives.
Trusted since its introduction in 1916, Trojan Brand Condomsis the legendary protector and defender of all that is good about sex.
Trojan Brand Condoms believes in responsible, great sex and triple test their condoms to ensure reliability.
Trojan Brand Condoms continues to explore new ways to help you enjoy the pleasure of respectful and responsible sex in every way possible.

ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs

Retrieved on:

Saturday, July 17, 2021

Health, Infectious diseases, Clinical trials, Research, Pharmaceutical, Science, Prevention of HIV/AIDS, HIV/AIDS, SALSA2, Dovato (dolutegravir/lamivudine)3,4, ViiV Healthcare, GSK, SALSA2, DOVATO (DOLUTEGRAVIR/LAMIVUDINE)3,4, VIIV HEALTHCARE, GSK

These findings give physicians another reason to feel confident switching virologically suppressed people to this 2-drug regimen.

Key Points:

These findings give physicians another reason to feel confident switching virologically suppressed people to this 2-drug regimen.
SALSA is the second switch study to demonstrate Dovatos non-inferior efficacy and high barrier to resistance, with no participants experiencing virologic failure in the Dovato arm of the study.
These findings demonstrate its versatility for participants who had previously been on a broad range of different regimens, cementing its place in the HIV treatment paradigm.
Overall adverse event (AE) rates were similar between the Dovato and CAR arms (73% [180/246] vs 70% [172/247], respectively).

ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19

Retrieved on:

Saturday, July 17, 2021

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.

Key Points:

Additionally, this regimen remained highly acceptable both to healthcare providers and people living with HIV and was strongly preferred by study participants to daily oral therapy.
A corresponding trial in Europe, CARISEL, is examining the implementation of long-acting cabotegravir and rilpivirine, dosed every 2-months in certain European healthcare settings.
Marketing Authorisations for the long-acting regimen of cabotegravir and rilpivirine were granted by the European Medicines Agency in December 2020.
Sustainment of implementation strategies was assessed via surveys and semi-structured interviews of staff study participants as well as patient study participants.

New Phase 3 Data Support the Sustained, Long-Acting Efficacy of Lenacapavir, Gilead's Investigational HIV-1 Capsid Inhibitor

Retrieved on:

Saturday, July 17, 2021

AIDS, Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Medical specialties, Hepatotoxins, Prevention of HIV/AIDS, HIV/AIDS, Management of HIV/AIDS, Zidovudine, HIV, Lenacapavir, Discovery and development of HIV-protease inhibitors, HIV vaccine development

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.

Key Points:

If approved, lenacapavir would be the first capsid inhibitor and the only HIV-1 treatment option administered every six months.
Lenacapavir is a potentially first-in-class capsid inhibitor without overlapping resistance with any currently approved antiretroviral therapy (ART).
Lenacapavir is a potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection.
Data presented at AIDS 2020 from a Phase 1 study support further evaluation of lenacapavir administered subcutaneously every six months for both HIV-1 treatment and prevention.

Merck Announces Presentation of New Data from Broad HIV Program at IAS 2021

Retrieved on:

Monday, July 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the companys HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21.

Key Points:

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of data from the companys HIV clinical development program at the 11th International AIDS Society Conference on HIV Science (IAS 2021) from July 18-21.
Additionally, Merck will share 96-week safety data for once-daily islatravir in combination with doravirine in previously untreated adults with HIV-1 infection.
Select abstracts in the IAS 2021 program include:
Safety and Pharmacokinetics of Oral Islatravir Once Monthly for HIV Pre-exposure Prophylaxis (PrEP): Week 24 Analysis of a Phase 2a Trial.
The Safety and Efficacy of Maintenance with Doravirine/Lamivudine/Tenofovir through 192 Weeks in Adults with HIV-1: Results from the DRIVE-AHEAD Clinical Trial.

Introducing Pleasure Finder, the first ever sexual education Google Assistant action dedicated to improving sexual health and performance

Retrieved on:

Tuesday, June 22, 2021

Harm reduction, Prevention of HIV/AIDS, Sex education, Sexuality and society, Human sexuality, Rape

The action helps users find out more about the health benefits of pleasure and open up about their sexual health - without fear of mockery or judgement.

Key Points:

The action helps users find out more about the health benefits of pleasure and open up about their sexual health - without fear of mockery or judgement.
It's the first time a voice assistant has been able to offer advice around sexual health, sexual education and performance, and has been specifically designed to answer questions people want to ask about sexual health but are sometimes too afraid to ask their partner or a healthcare professional.
And it couldn't be simpler to use: users can just say to "Ok Google, let me speak to Pleasure Finder" and go from there.
The action will outline all the different forms of advice and help it can offer, ensuring everyone can get the sexual wellness advice they need.

BlueCity's He Health to introduce online consultation services and expand PEP delivery network

Retrieved on:

Monday, June 21, 2021

Clinical medicine, Medicine, Medical specialties, Ejaculation, Male genital disorders, HIV/AIDS, Post-exposure prophylaxis, Prevention of HIV/AIDS, Premature ejaculation, Ro, Blued

BEIJING, June, 21, 2021 /PRNewswire/ --BlueCity(Nasdaq: BLCT) today announced thatHe Health, the brand's health service platform for men, will introduce comprehensive online consultation services and expand its PEP (post-exposure prophylaxis) express delivery network in the second half of this year.

Key Points:

BEIJING, June, 21, 2021 /PRNewswire/ --BlueCity(Nasdaq: BLCT) today announced thatHe Health, the brand's health service platform for men, will introduce comprehensive online consultation services and expand its PEP (post-exposure prophylaxis) express delivery network in the second half of this year.
It also enables He Health to provide a more complete set of health services from men's health consultations to advice on issues like Erectile Dysfunction, Premature Ejaculation, HIV testing and prevention, and more, as well as drug accessibility services.
Meanwhile, coverage for the two-hour PEP delivery services during working hours will be extended from 40 cities to 100 in China by the end of this year.
BlueCity's mobile app Blued enables users to conveniently and safely connect with each other, express themselves and access professional health-related services.

Penn Dental Medicine Study Shows How HIV Infection Impacts Brain's White Matter

Retrieved on:

Friday, June 18, 2021

Hepatotoxins, Medical specialties, Prevention of HIV/AIDS, Retroviridae, Health, HIV/AIDS, Pandemics, HIV, Oligodendrocyte, Zidovudine, HIV-associated neurocognitive disorder

PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.

Key Points:

PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains.
Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)the lifesaving drugs that many with HIV use dailycan reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production.
"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto , professor at Penn Dental Medicine and the study's co-senior author.